Phosphoglycolohydroxamate (PGH) is a synthetic compound that acts as a potent inhibitor of various enzymes involved in the biosynthesis of purines and pyrimidines. It is known to inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT), an essential enzyme in the purine biosynthesis pathway. PGH's inhibitory effect on GARFT is highly specific and has been shown to effectively block the production of purines. This inhibition leads to a depletion of cellular nucleotide pools, ultimately hindering cell growth and proliferation. Studies on PGH have focused on its potential as an anti-cancer agent due to its ability to target key metabolic pathways involved in tumor cell growth and survival. The compound's mechanism of action, its selectivity for GARFT, and its impact on purine biosynthesis make it an intriguing target for further research in the development of novel cancer therapies.'
phosphoglycolohydroxamate: inhibits DHAP (dihydroxyacetone phosphate)-converting enzymes; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
phosphoglycolohydroxamic acid : The hydroxamate of phosphoglycolic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 4797 |
CHEMBL ID | 371668 |
CHEBI ID | 28475 |
SCHEMBL ID | 4309631 |
MeSH ID | M0053127 |
Synonym |
---|
acetamide, n-hydroxy-2-(phosphonooxy)- |
PGH , |
phosphoglycolohydroxamic acid |
1TRD |
1IK4 |
DB02739 |
1TPW , |
DB03026 |
phosphoglycolohydroxamate |
2-(hydroxyamino)-2-oxoethyl dihydrogen phosphate |
CHEBI:28475 , |
51528-59-7 |
bdbm50167777 |
CHEMBL371668 , |
phosphoric acid monohydroxycarbamoylmethyl ester |
SCHEMBL4309631 |
DTXSID90199497 |
Q27093998 |
2-(hydroxyamino)-2-oxoethyldihydrogenphosphate |
[(hydroxycarbamoyl)methoxy]phosphonic acid |
HY-148077 |
CS-0610369 |
Role | Description |
---|---|
EC 5.3.1.1 (triose-phosphate isomerase) inhibitor | Any EC 5.3.1.* (intramolecular oxidoreductase interconverting aldoses and ketoses) inhibitor that interferes with the action of a triose-phosphate isomerase (EC 5.3.1.1). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
amidoalkyl phosphate | |
hydroxamic acid | A compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Methylglyoxal Synthase | Escherichia coli | Ki | 0.0390 | 0.0390 | 0.0390 | 0.0390 | AID977610 |
Chain F, Methylglyoxal Synthase | Escherichia coli | Ki | 0.0390 | 0.0390 | 0.0390 | 0.0390 | AID977610 |
Chain B, TRIOSEPHOSPHATE ISOMERASE | Trypanosoma brucei brucei | Ki | 4.0000 | 4.0000 | 4.0000 | 4.0000 | AID977610 |
Fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Ki | 1.0000 | 1.0000 | 1.0000 | 1.0000 | AID257659 |
Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 | Ki | 0.0100 | 0.0100 | 0.0100 | 0.0100 | AID257660 |
Triosephosphate isomerase | Homo sapiens (human) | Ki | 3.5000 | 3.0000 | 3.5000 | 4.0000 | AID292822; AID594834 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
glycolytic process | Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 |
glycolytic process | Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 |
gluconeogenesis | Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 |
gluconeogenesis | Triosephosphate isomerase | Homo sapiens (human) |
methylglyoxal biosynthetic process | Triosephosphate isomerase | Homo sapiens (human) |
glyceraldehyde-3-phosphate biosynthetic process | Triosephosphate isomerase | Homo sapiens (human) |
canonical glycolysis | Triosephosphate isomerase | Homo sapiens (human) |
glycolytic process | Triosephosphate isomerase | Homo sapiens (human) |
glycerol catabolic process | Triosephosphate isomerase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytosol | Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 |
cytosol | Fructose-bisphosphate aldolase class 2 | Escherichia coli K-12 |
extracellular space | Triosephosphate isomerase | Homo sapiens (human) |
nucleus | Triosephosphate isomerase | Homo sapiens (human) |
cytosol | Triosephosphate isomerase | Homo sapiens (human) |
extracellular exosome | Triosephosphate isomerase | Homo sapiens (human) |
cytosol | Triosephosphate isomerase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1811 | Experimentally measured binding affinity data derived from PDB | 2001 | Biochemistry, Jun-12, Volume: 40, Issue:23 | Mechanistic implications of methylglyoxal synthase complexed with phosphoglycolohydroxamic acid as observed by X-ray crystallography and NMR spectroscopy. |
AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2001 | Biochemistry, Jun-12, Volume: 40, Issue:23 | Mechanistic implications of methylglyoxal synthase complexed with phosphoglycolohydroxamic acid as observed by X-ray crystallography and NMR spectroscopy. |
AID292822 | Inhibition of triosephosphate isomerase | 2007 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2 | New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase. |
AID68946 | Selectivity (Ki rabbit /Ki yeast) of inhibitors for class II versus class I FBP aldolase | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases. |
AID292820 | Inhibition of class I FBA | 2007 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2 | New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase. |
AID68939 | In vitro binding affinity towards FBP aldolase from yeast | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases. |
AID257659 | Inhibitory activity against class I FBP aldolase from rabbit | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase. |
AID257660 | Inhibitory activity against class II FBP aldolase from Escherichia coli | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase. |
AID238281 | Binding affinity against class II fructose-bisphosphate aldolase | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | New inhibitors of rabbit muscle triose-phosphate isomerase. |
AID292821 | Inhibition of class II FBA | 2007 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2 | New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase. |
AID68942 | In vitro binding towards FBP aldolase from rabbit | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases. |
AID594834 | Inhibition of Triosephosphate isomerase | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis. |
AID292823 | Inhibition of rabbit muscle NADH-dependent cytosolic glycerophosphate dehydrogenase | 2007 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2 | New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase. |
AID238454 | Binding affinity against rabbit muscle triose-phosphate isomerase | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | New inhibitors of rabbit muscle triose-phosphate isomerase. |
AID1811 | Experimentally measured binding affinity data derived from PDB | 1993 | Proteins, Aug, Volume: 16, Issue:4 | Structures of the "open" and "closed" state of trypanosomal triosephosphate isomerase, as observed in a new crystal form: implications for the reaction mechanism. |
AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 1993 | Proteins, Aug, Volume: 16, Issue:4 | Structures of the "open" and "closed" state of trypanosomal triosephosphate isomerase, as observed in a new crystal form: implications for the reaction mechanism. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (3.57) | 18.7374 |
1990's | 10 (35.71) | 18.2507 |
2000's | 9 (32.14) | 29.6817 |
2010's | 8 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |